234 related articles for article (PubMed ID: 25095806)
1. Rifaximin: beyond the traditional antibiotic activity.
Calanni F; Renzulli C; Barbanti M; Viscomi GC
J Antibiot (Tokyo); 2014 Sep; 67(9):667-70. PubMed ID: 25095806
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.
Scarpignato C; Pelosini I
Chemotherapy; 2005; 51 Suppl 1():36-66. PubMed ID: 15855748
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin pharmacology and clinical implications.
Ojetti V; Lauritano EC; Barbaro F; Migneco A; Ainora ME; Fontana L; Gabrielli M; Gasbarrini A
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):675-82. PubMed ID: 19442033
[TBL] [Abstract][Full Text] [Related]
4. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.
Scarpignato C; Pelosini I
Digestion; 2006; 73 Suppl 1():13-27. PubMed ID: 16498249
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
[TBL] [Abstract][Full Text] [Related]
6. Biologic properties and clinical uses of rifaximin.
DuPont HL
Expert Opin Pharmacother; 2011 Feb; 12(2):293-302. PubMed ID: 21226639
[TBL] [Abstract][Full Text] [Related]
7. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.
Cottreau J; Baker SF; DuPont HL; Garey KW
Expert Rev Anti Infect Ther; 2010 Jul; 8(7):747-60. PubMed ID: 20586560
[TBL] [Abstract][Full Text] [Related]
9. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation.
Ponziani FR; Zocco MA; D'Aversa F; Pompili M; Gasbarrini A
World J Gastroenterol; 2017 Jul; 23(25):4491-4499. PubMed ID: 28740337
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases.
DuPont HL
Mayo Clin Proc; 2015 Aug; 90(8):1116-24. PubMed ID: 26162610
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin: in vitro and in vivo antibacterial activity--a review.
Jiang ZD; DuPont HL
Chemotherapy; 2005; 51 Suppl 1():67-72. PubMed ID: 15855749
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.
Adachi JA; DuPont HL
Clin Infect Dis; 2006 Feb; 42(4):541-7. PubMed ID: 16421799
[TBL] [Abstract][Full Text] [Related]
13. Use of rifaximin in gastrointestinal and liver diseases.
Shayto RH; Abou Mrad R; Sharara AI
World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin--a novel antimicrobial for enteric infections.
Huang DB; DuPont HL
J Infect; 2005 Feb; 50(2):97-106. PubMed ID: 15667909
[TBL] [Abstract][Full Text] [Related]
15. Review article: the antimicrobial effects of rifaximin on the gut microbiota.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():3-10. PubMed ID: 26618921
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.
Gerard L; Garey KW; DuPont HL
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):201-11. PubMed ID: 15918778
[TBL] [Abstract][Full Text] [Related]
17. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides.
Chen LF; Kaye D
Infect Dis Clin North Am; 2009 Dec; 23(4):1053-75, x. PubMed ID: 19909897
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin intake leads to emergence of rifampin-resistant staphylococci.
Valentin T; Leitner E; Rohn A; Zollner-Schwetz I; Hoenigl M; Salzer HJ; Krause R
J Infect; 2011 Jan; 62(1):34-8. PubMed ID: 21073894
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders].
Gasztonyi B; Hunyady B
Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship.
Gao J; Gillilland MG; Owyang C
Gut Microbes; 2014 Jul; 5(4):571-5. PubMed ID: 25244596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]